AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28877754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with Zika-like symptoms during pregnancy
Number of subjects: 0
Study 28877754 — intervention group
Group type: COMPARATOR
Intervention: Non-microcephalic babies
Number of subjects: 0
Study 28877754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers classified as homemakers with past dengue infections
Number of subjects: 0
Study 28877863 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream, applied three times a week for 16 weeks
Number of subjects: 20
Study 28877863 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream
Number of subjects: 20
Study 28877894 — intervention group
Group type: EXPERIMENTAL
Intervention: Later circadian timing of food intake
Number of subjects: 0
Study 28877944 — intervention group
Group type: EXPERIMENTAL
Intervention: External inspections of sepsis detection and treatment
Number of subjects: 24
Study 28877948 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 440
Study 28877948 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline adherence for stable CAD patients
Number of subjects: 440
Study 28877948 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart team evaluation
Number of subjects: 440
Study 28877948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemia testing
Number of subjects: 440
Study 28878005 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate Anticoagulant
Number of subjects: 0
Study 28878616 — intervention group
Group type: EXPERIMENTAL
Intervention: New electronic subretinal implant Alpha AMS
Number of subjects: 15
Study 28878616 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study 28878889 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid volume optimization with hydroxyethyl starch and crystalloid fluid
Number of subjects: 97
Study 28878932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle program (the VEND-RISK Study)
Number of subjects: 332
Study 28878934 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 110740
Study 28879035 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme with 2 days of lectures (group 1, 2, and 3) and bimonthly telephone calls
Number of subjects: 198
Study 28879038 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional and individualised neuromuscular exercise therapy (ET), 12 weeks, 3 sessions per week supervised by trained physical therapists.
Number of subjects: 60
Study 28879038 — intervention group
Group type: COMPARATOR
Intervention: No attention control group (CG).
Number of subjects: 60
Study 28879040 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcium channel blocker (CCB) with angiotensin receptor blocker (ARB)
Number of subjects: 119
Study 28879040 — intervention group
Group type: COMPARATOR
Intervention: Combination of thiazide diuretic with angiotensin receptor blocker (ARB)
Number of subjects: 119
Study 28879040 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcium channel blocker (CCB) with ARB
Number of subjects: 119
Study 28879040 — intervention group
Group type: COMPARATOR
Intervention: Combination of thiazide diuretic with ARB
Number of subjects: 119
Study 28879043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automated digital joint space width measurement
Number of subjects: 96
Study 28879043 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiographic scoring method (SHS)
Number of subjects: 96
Study 28879052 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI >30)
Number of subjects: 260
Study 28879052 — intervention group
Group type: COMPARATOR
Intervention: Non-obese patients (BMI <30)
Number of subjects: 260
Study 28879052 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 260
Study 28879052 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 260
Study 28879052 — intervention group
Group type: EXPERIMENTAL
Intervention: HAQ (per-unit increase)
Number of subjects: 260
Study 28879052 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 260
Study 28879248 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival crevicular fluid (GCF) levels of multiple cytokines and chemokines and RANKL:OPG ratio
Number of subjects: 58
Study 28879248 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-12p40, IL-6, IL-12p70, IL-2, and MIP-1α
Number of subjects: 58
Study 28879248 — intervention group
Group type: COMPARATOR
Intervention: Plasma RANKL levels
Number of subjects: 58
Study 28879248 — intervention group
Group type: COMPARATOR
Intervention: Plasma inflammatory profile including MIP-1α, IL-8, IL-10, and INF-γ
Number of subjects: 58
Study 28879247 — intervention group
Group type: EXPERIMENTAL
Intervention: JP2 sequence
Number of subjects: 0
Study 28879247 — intervention group
Group type: COMPARATOR
Intervention: non-JP2 sequence
Number of subjects: 0
Study 28879519 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 0
Study 28880374 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (HC) treatment
Number of subjects: 21
Study 28880374 — intervention group
Group type: COMPARATOR
Intervention: Untreated SCD patients
Number of subjects: 21
Study 28880921 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary proteomic (UP) classifiers
Number of subjects: 352
Study 28880943 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-PV mediated AF
Number of subjects: 229
Study 28880943 — intervention group
Group type: COMPARATOR
Intervention: PV-mediated AF
Number of subjects: 229
Study 28881165 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0
Study 28881165 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28881319 — intervention group
Group type: EXPERIMENTAL
Intervention: 25mg intravenous (IV) cocaine
Number of subjects: 8
Study 28881389 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIg)
Number of subjects: 0
Study 28881389 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 0
Study 28881839 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC) 20mg/m²
Number of subjects: 0
Study 28881904 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive status in Barrett's esophagus patients
Number of subjects: 180
Study 28881904 — intervention group
Group type: COMPARATOR
Intervention: HPV positive status in control patients
Number of subjects: 180
Study 28881904 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of HPV with Barrett's esophagus
Number of subjects: 180
Study 28881904 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with HPV
Number of subjects: 180
Study 28881904 — intervention group
Group type: EXPERIMENTAL
Intervention: Significance of HPV in the etiology of BE
Number of subjects: 180
Study 28882117 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire regarding eye diseases awareness and practices
Number of subjects: 323
Study 28882127 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty Index (FI) derived from Swiss RAI-HC
Number of subjects: 3714
Study 28882127 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse health outcomes (falls, hospitalizations, mortality)
Number of subjects: 3714
Study 28882141 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional laparoscopy
Number of subjects: 400
Study 28882141 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 400
Study 28882349 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium clip-screw implant system
Number of subjects: 6
Study 28882396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 32
Study 28882396 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 32
Study 28882436 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600mg twice daily (BID)
Number of subjects: 106
Study 28882436 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600mg BID
Number of subjects: 106
Study 28882565 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium absorption study
Number of subjects: 20
Study 28882811 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (coffee sachets with caffeine)
Number of subjects: 66
Study 28882811 — intervention group
Group type: COMPARATOR
Intervention: Placebo (coffee sachets without caffeine)
Number of subjects: 66
Study 28883080 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunophenotypic expression profile
Number of subjects: 769
Study 28883090 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk (ISW) before and after pulmonary rehabilitation (PR)
Number of subjects: 122
Study 28883090 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk (ISW)
Number of subjects: 122
Study 28883090 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum clinically important difference (MCID) estimates
Number of subjects: 122
Study 28883894 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP patients
Number of subjects: 20
Study 28883894 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 28883928 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble continuous positive airway pressure (bCPAP)
Number of subjects: 900
Study 28883928 — intervention group
Group type: COMPARATOR
Intervention: Low-flow oxygen (standard care)
Number of subjects: 900
Study 28883932 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 international units per day of oral vitamin D
Number of subjects: 0
Study 28883932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28884264 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC-CVHR algorithms applied to ECG data
Number of subjects: 47
Study 28884487 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 10
Study 28884840 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (first dose)
Number of subjects: 0
Study 28884840 — intervention group
Group type: COMPARATOR
Intervention: Hydroxycarbamide (chronic therapy)
Number of subjects: 0
Study 28885470 — intervention group
Group type: COMPARATOR
Intervention: Syndecan-1 concentrations within 10 hours of injury
Number of subjects: 17
Study 28885470 — intervention group
Group type: COMPARATOR
Intervention: Thrombomodulin concentrations within 10 hours of injury
Number of subjects: 17
Study 28885930 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (TLCs) including exercise, nutrition/diet, stress management and relaxation, time in nature, relationships, service to others, religious or spiritual involvement, and recreation.
Number of subjects: 74
Study 28885930 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (TLCs) through four classes and individual counseling over 9 weeks.
Number of subjects: 74
Study 28886213 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (BMI ≥30)
Number of subjects: 600
Study 28886213 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight group (BMI 18.5-29.9)
Number of subjects: 600
Study 28886213 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight group (BMI <18.5)
Number of subjects: 600
Study 28886213 — intervention group
Group type: COMPARATOR
Intervention: All groups compared
Number of subjects: 600
Study 28886760 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) at 5 Hz, delivered in up to 40 daily sessions to the left dorsolateral prefrontal cortex
Number of subjects: 33
Study 28887375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular alteplase
Number of subjects: 464
Study 28887375 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 464
Study 28887375 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF inflammatory measures
Number of subjects: 464
Study 28887375 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial IVH volume exceeding 20 mL
Number of subjects: 464
Study 28887375 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-positive CSF bacterial infection
Number of subjects: 464
Study 28887751 — intervention group
Group type: EXPERIMENTAL
Intervention: Risky Sex class (n = 72, 28%)
Number of subjects: 641
Study 28887751 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Sexual Risk class (n = 190, 73%)
Number of subjects: 641
Study 28887751 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Using, Violence-Exposed, and Impaired Sex class (n = 53; 14%)
Number of subjects: 641
Study 28887751 — intervention group
Group type: EXPERIMENTAL
Intervention: Risky Sex and Moderate Drinking class (n = 326; 86%)
Number of subjects: 641
Study 28887801 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous belimumab 200 mg once weekly plus standard of care
Number of subjects: 687
Study 28887801 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous belimumab 200 mg once weekly
Number of subjects: 687
Study 28888148 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM
Number of subjects: 1153
Study 28888148 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM
Number of subjects: 1153
Study 28888148 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM and T2DM
Number of subjects: 1153
Study 28889107 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from phosphodiesterase-5 inhibitors (PDE5i) to riociguat
Number of subjects: 0
Study 28889769 — intervention group
Group type: EXPERIMENTAL
Intervention: Orsiro biodegradable polymer drug-eluting stent (BP-DES)
Number of subjects: 0
Study 28889769 — intervention group
Group type: COMPARATOR
Intervention: Xience durable polymer drug-eluting stent (DP-DES)
Number of subjects: 0
Study 28890218 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorooctanoic acid (PFOA)
Number of subjects: 402
Study 28890218 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorohexanesulfonic acid
Number of subjects: 402
Study 28890218 — intervention group
Group type: EXPERIMENTAL
Intervention: PFOA and perfluorononanoic acid
Number of subjects: 402
Study 28890439 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 0
Study 28890439 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28890833 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 0
Study 28891911 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 0
Study 28891911 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging techniques (functional MRI, diffusion tensor imaging, arterial spin labeling)
Number of subjects: 0
Study 28892085 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating endothelial cell count (CEC) analysis using the CellSearch system
Number of subjects: 90
Study 28892085 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand evaluation of CEC counts
Number of subjects: 90
Study 28892085 — intervention group
Group type: EXPERIMENTAL
Intervention: CEC changes during allo-HSCT
Number of subjects: 90
Study 28892218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, adjustable to 25 or 100 mg based on efficacy and safety, taken ~1 hour before sexual activity, not more than once daily)
Number of subjects: 997
Study 28892218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 997
Study 28892218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 997
Study 28893304 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulating the host immune system to resist HIV infection (specific intervention details not provided)
Number of subjects: 0
Study 28893386 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28893549 — intervention group
Group type: EXPERIMENTAL
Intervention: aCRT
Number of subjects: 0
Study 28893549 — intervention group
Group type: COMPARATOR
Intervention: convCRT
Number of subjects: 0
Study 28893761 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin distribution with a coverage target of 90% for 4 days
Number of subjects: 24
Study 28893761 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin distribution with a coverage target of 80% for 1 day
Number of subjects: 24
Study 28893761 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 24
Study 28893770 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffold
Number of subjects: 29
Study 28893779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam 1.5 g every 8 hours (q8h)
Number of subjects: 0
Study 28893813 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid-insured visits after ACA implementation in expansion states
Number of subjects: 870319
Study 28893813 — intervention group
Group type: EXPERIMENTAL
Intervention: Privately insured visits in nonexpansion states
Number of subjects: 870319
Study 28893813 — intervention group
Group type: COMPARATOR
Intervention: Uninsured visits for non-Hispanic white patients in expansion states
Number of subjects: 870319
Study 28893813 — intervention group
Group type: COMPARATOR
Intervention: Relative change in uninsured visits between expansion and nonexpansion states
Number of subjects: 870319
Study 28894606 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-retained cryopreserved amniotic membrane (CAM)
Number of subjects: 20
Study 28894606 — intervention group
Group type: COMPARATOR
Intervention: Conventional maximum treatment (control)
Number of subjects: 20
Study 28894792 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow MSCs
Number of subjects: 0
Study 28898284 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise for 6 minutes
Number of subjects: 27
Study 28898890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone, mean daily dose of 2,091.1 mg, mean exposure of 122 weeks (SD 98), median exposure of 88 weeks (range >0 to 349 weeks)
Number of subjects: 1058
Study 28898890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 1058
Study 28899363 — intervention group
Group type: EXPERIMENTAL
Intervention: LJM716 40 mg/kg QW
Number of subjects: 54
Study 28899363 — intervention group
Group type: EXPERIMENTAL
Intervention: LJM716
Number of subjects: 54
Study 28899394 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention for reentry veterans
Number of subjects: 600000
Study 28899434 — intervention group
Group type: EXPERIMENTAL
Intervention: Care Group model with social and behavior change communication (SBCC)
Number of subjects: 0
Study 28899517 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of OSA
Number of subjects: 113
Study 28899517 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment of OSA
Number of subjects: 113
Study 28899517 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 113
Study 28899517 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention
Number of subjects: 113
Study 28899825 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted neuroprostheses (NPs) for lower extremity function
Number of subjects: 22
Study 28899825 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation implanted pulse generator (IPG) and epimysial electrodes
Number of subjects: 22
Study 28899825 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation IPG along with intramuscular and nerve cuff electrodes
Number of subjects: 22
Study 28899825 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical and clinical performance of implanted LE NPs
Number of subjects: 22
Study 28900040 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid nebulization (2.8 mol/L)
Number of subjects: 42
Study 28900040 — intervention group
Group type: COMPARATOR
Intervention: Control (stroke subjects without dysphagia or aspiration)
Number of subjects: 42
Study 28900041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough Peak Flow (CPF) measured using a ventilator flow meter before extubation
Number of subjects: 92
Study 28900041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough Peak Flow (CPF) measured using a ventilator flow meter
Number of subjects: 92
Study 28900115 — intervention group
Group type: EXPERIMENTAL
Intervention: ADI-PEG20
Number of subjects: 43
Study 28900544 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspira-aA (Human Optics)
Number of subjects: 60
Study 28900544 — intervention group
Group type: COMPARATOR
Intervention: Tecnis ZCB00 (Abbott Medical Optics)
Number of subjects: 60
Study 28900714 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a (PEGASYS®, 180 µg/week) plus ribavirin (COPEGUS®, 1000/1200 mg/day in genotypes (GT) 1/4 and 800 mg/day in GT 2/3) for 24-72 weeks
Number of subjects: 88
Study 28900714 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 88
Study 28900875 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly for 24 weeks
Number of subjects: 85
Study 28902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to isoniazid
Number of subjects: 308
Study 28902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to ofloxacin
Number of subjects: 308
Study 28902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to moxifloxacin at 0.5 μg/mL
Number of subjects: 308
Study 28902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to moxifloxacin at 2.0 μg/mL
Number of subjects: 308
Study 28902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to kanamycin
Number of subjects: 308
Study 28902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to amikacin
Number of subjects: 308
Study 28902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to isoniazid using DNA sequencing
Number of subjects: 308
Study 28902596 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational assay for detecting resistance to fluoroquinolones using DNA sequencing
Number of subjects: 308